Gianluca Vanni1, Giovanni Tazzioli2, Marco Pellicciaro3, Marco Materazzo1, Orsaria Paolo4, Francesca Cattadori5, Francesca Combi2,4,5,6, Simona Papi2, Chiara Adriana Pistolese7, Maria Cotesta1, Francesca Santori1, Jonathan Caspi8, Agostino Chiaravalloti9,10, Saverio Muscoli11, Vittorio Lombardo12, Antonella Grasso4, Lorenza Caggiati4, Roberta Raselli5, Dante Palli5, Vittorio Altomare4, Rolando Maria D'Angelillo13, Leonardo Palombi9, Oreste Claudio Buonomo1. 1. Breast Unit, Department of Surgical Science, PTV: Policlinico Tor Vergata University, Rome, Italy. 2. Division of Breast Surgical Oncology Department of Medical and Surgery, Maternal-infantile and Adult Sciences, University Hospital of Modena and Reggio Emilia, Modena, Italy. 3. Breast Unit, Department of Surgical Science, PTV: Policlinico Tor Vergata University, Rome, Italy; marcopell62@gmail.com. 4. Department of Breast Surgery, University Campus Bio-Medico, Rome, Italy. 5. Breast Surgery, Breast Unit, "Guglielmo da Saliceto" Hospital, Piacenza, Italy. 6. PhD Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy. 7. Department of Diagnostic Imaging and Interventional Radiology, Molecular Imaging and Radiotherapy, Policlinico Tor Vergata University, Rome, Italy. 8. Tor Vergata School of Medicine and Surgery, Tor Vergata University, Rome, Italy. 9. Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy. 10. IRCCS Neuromed, UOC Medicina Nucleare, Pozzilli, Italy. 11. Department of Cardiovascular Disease, Tor Vergata University, Rome, Italy. 12. Department of General Surgery, I.R.C.C.S. Centro Neurolesi Bonino Pulejo P.O. Piemnote, Messina, Italy. 13. Radiotherapy Unit, Department of Oncology and Hematology, Policlinico Tor Vergata University, Rome, Italy.
Abstract
BACKGROUND/AIM: Extraordinary restrictions aimed to limit Sars-CoV-2 spreading; they imposed a total reorganization of the health-system. Oncological treatments experienced a significant slowdown. The aim of our multicentric retrospective study was to evaluate screening suspension and surgical treatment delay during COVID-19 and the impact on breast cancer presentation. PATIENTS AND METHODS: All patients who underwent breast surgery from March 11, 2020 to May 30, 2020 were evaluated and considered as the Lockdown group. These patients were compared with similar patients of the previous year, the Pre-Lockdown group. RESULTS: A total of 432 patients were evaluated; n=223 and n=209 in the Lockdown and Pre-lockdown-groups, respectively. At univariate analysis, waiting times, lymph-nodes involvement and cancer grading, showed a statistically significant difference (p<0.05). Multivariate analysis identified waiting-time on list (OR=1.07) as a statistically significant predictive factor of lymph node involvement. CONCLUSION: Although we did not observe a clinically evident difference in breast cancer presentation, we reported an increase in lymph node involvement.
BACKGROUND/AIM: Extraordinary restrictions aimed to limit Sars-CoV-2 spreading; they imposed a total reorganization of the health-system. Oncological treatments experienced a significant slowdown. The aim of our multicentric retrospective study was to evaluate screening suspension and surgical treatment delay during COVID-19 and the impact on breast cancer presentation. PATIENTS AND METHODS: All patients who underwent breast surgery from March 11, 2020 to May 30, 2020 were evaluated and considered as the Lockdown group. These patients were compared with similar patients of the previous year, the Pre-Lockdown group. RESULTS: A total of 432 patients were evaluated; n=223 and n=209 in the Lockdown and Pre-lockdown-groups, respectively. At univariate analysis, waiting times, lymph-nodes involvement and cancer grading, showed a statistically significant difference (p<0.05). Multivariate analysis identified waiting-time on list (OR=1.07) as a statistically significant predictive factor of lymph node involvement. CONCLUSION: Although we did not observe a clinically evident difference in breast cancer presentation, we reported an increase in lymph node involvement.
Authors: Carole Mathelin; Shanti Ame; Stanley Anyanwu; Eli Avisar; Wahib Mohcen Boubnider; Katrin Breitling; Hannah Ayettey Anie; José Carlos Conceição; Veronique Dupont; Elisabeth Elder; Constanze Elfgen; Tony Elonge; Edelmiro Iglesias; Shigeru Imoto; Lydia Ioannidou-Mouzaka; Elisabeth A Kappos; Martin Kaufmann; Michael Knauer; Franck Luzuy; Marko Margaritoni; Mamadou Mbodj; Alexander Mundinger; Ruben Orda; Valerijus Ostapenko; Serdar Özbaş; Vahit Özmen; Olivia Pagani; Tadeusz Pieńkowski; Schlomo Schneebaum; Ekaterina Shmalts; Ashraf Selim; Zotov Pavel; Massimo Lodi; Maurício Maghales-Costa Journal: Eur J Breast Health Date: 2021-03-31
Authors: Annie Tang; Elad Neeman; Brooke Vuong; Vignesh A Arasu; Raymond Liu; Gillian E Kuehner; Alison C Savitz; Liisa L Lyon; Prachi Anshu; Samantha A Seaward; Milan D Patel; Laurel A Habel; Lawrence H Kushi; Margaret Mentakis; Eva S Thomas; Tatjana Kolevska; Sharon B Chang Journal: Breast Cancer Res Treat Date: 2022-01-06 Impact factor: 4.624
Authors: Sofía Ruiz-Medina; Silvia Gil; Begoña Jimenez; Pablo Rodriguez-Brazzarola; Tamara Diaz-Redondo; Mireya Cazorla; Marta Muñoz-Ayllon; Inmaculada Ramos; Carmen Reyna; María José Bermejo; Ana Godoy; Esperanza Torres; Manuel Cobo; Laura Galvez; Antonio Rueda; Emilio Alba; Nuria Ribelles Journal: Cancers (Basel) Date: 2021-06-28 Impact factor: 6.575